Cargando…
Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
Mental illnesses are a global health challenge, and effective medicines are needed to treat these conditions. Psychotropic drugs are commonly prescribed to manage mental disorders, such as schizophrenia, but unfortunately, they can cause significant and undesirable side effects, such as myocarditis,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142280/ https://www.ncbi.nlm.nih.gov/pubmed/37111360 http://dx.doi.org/10.3390/ph16040603 |
_version_ | 1785033575619362816 |
---|---|
author | Mlambo, Ronald Liu, Jia Wang, Qian Tan, Songwen Chen, Chuanpin |
author_facet | Mlambo, Ronald Liu, Jia Wang, Qian Tan, Songwen Chen, Chuanpin |
author_sort | Mlambo, Ronald |
collection | PubMed |
description | Mental illnesses are a global health challenge, and effective medicines are needed to treat these conditions. Psychotropic drugs are commonly prescribed to manage mental disorders, such as schizophrenia, but unfortunately, they can cause significant and undesirable side effects, such as myocarditis, erectile dysfunction, and obesity. Furthermore, some schizophrenic patients may not respond to psychotropic drugs, a condition called schizophrenia-treatment resistance. Fortunately, clozapine is a promising option for patients who exhibit treatment resistance. Unlike chlorpromazine, scientists have found that clozapine has fewer neurological side effects. Additionally, olanzapine and aripiprazole are well-known for their moderating effects on psychosis and are widely used in clinical practice. To further maximize drug efficacy, it is critical to deeply understand the receptors or signaling pathways central to the nervous system, such as serotonin, histamine, trace amines, dopamine, and G-protein coupled receptors. This article provides an overview of the receptors mentioned above, as well as the antipsychotics that interact with them, such as olanzapine, aripiprazole, clozapine, and chlorpromazine. Additionally, this article discusses the general pharmacology of these medications. |
format | Online Article Text |
id | pubmed-10142280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101422802023-04-29 Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders Mlambo, Ronald Liu, Jia Wang, Qian Tan, Songwen Chen, Chuanpin Pharmaceuticals (Basel) Review Mental illnesses are a global health challenge, and effective medicines are needed to treat these conditions. Psychotropic drugs are commonly prescribed to manage mental disorders, such as schizophrenia, but unfortunately, they can cause significant and undesirable side effects, such as myocarditis, erectile dysfunction, and obesity. Furthermore, some schizophrenic patients may not respond to psychotropic drugs, a condition called schizophrenia-treatment resistance. Fortunately, clozapine is a promising option for patients who exhibit treatment resistance. Unlike chlorpromazine, scientists have found that clozapine has fewer neurological side effects. Additionally, olanzapine and aripiprazole are well-known for their moderating effects on psychosis and are widely used in clinical practice. To further maximize drug efficacy, it is critical to deeply understand the receptors or signaling pathways central to the nervous system, such as serotonin, histamine, trace amines, dopamine, and G-protein coupled receptors. This article provides an overview of the receptors mentioned above, as well as the antipsychotics that interact with them, such as olanzapine, aripiprazole, clozapine, and chlorpromazine. Additionally, this article discusses the general pharmacology of these medications. MDPI 2023-04-17 /pmc/articles/PMC10142280/ /pubmed/37111360 http://dx.doi.org/10.3390/ph16040603 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mlambo, Ronald Liu, Jia Wang, Qian Tan, Songwen Chen, Chuanpin Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders |
title | Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders |
title_full | Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders |
title_fullStr | Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders |
title_full_unstemmed | Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders |
title_short | Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders |
title_sort | receptors involved in mental disorders and the use of clozapine, chlorpromazine, olanzapine, and aripiprazole to treat mental disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142280/ https://www.ncbi.nlm.nih.gov/pubmed/37111360 http://dx.doi.org/10.3390/ph16040603 |
work_keys_str_mv | AT mlamboronald receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders AT liujia receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders AT wangqian receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders AT tansongwen receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders AT chenchuanpin receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders |